124
Participants
Start Date
October 31, 2010
Primary Completion Date
January 31, 2013
Study Completion Date
June 30, 2013
Menotrophin
Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
Follitrophin alpha
Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
Cetrorelix
Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
Choriongonadotropin
10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles \>+17 mm diameter as shown by pelvic ultrasound examination.
Progesterone
Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
Fertility Center Berlin, Berlin
Praxisklinik Sydow am Gendarmenmarkt, Berlin
Kinderwunschzentrum Dortmund, Dortmund
Universitätsklinikum Duesseldorf, Frauenklinik, Düsseldorf
Praxis für Kinderwunschbehandlung, Erlangen
NOVUM Zentrum, Essen
IVF Zentrum, Saar
Endokrinologikum Ulm, Ulm
Lead Sponsor
Collaborators (1)
Ferring Arzneimittel GmbH
INDUSTRY
Ferring Pharmaceuticals
INDUSTRY